Top

Published in:

01-08-2016 | Review

Kidney involvement in medium- and large-vessel vasculitis

Authors: Federica Maritati, Francesco Iannuzzella, Maria P. Pavia, Sonia Pasquali, Augusto Vaglio

Published in: Journal of Nephrology | Issue 4/2016

Abstract

Medium- and large-vessel vasculitides (MVV and LVV, respectively) comprise a heterogeneous group of disorders whose common denominator is the inflammatory involvement of vessels of medium and large size. This disease spectrum includes giant-cell arteritis and Takayasu’s arteritis, which typically affect the aorta and its main branches, and Kawasaki’s disease and polyarteritis nodosa, which involve medium-sized arteries. Chronic periaortitis, characterized by a perivascular fibro-inflammatory reaction affecting the abdominal aorta and the periaortic tissue, frequently has a systemic distribution, involving other segments of the aorta and its major branches, and could thus be included in this group. Unlike small-vessel vasculitides, MVV and LVV do not cause glomerulonephritis, although glomerular immune-mediated lesions and tubulo-interstitial nephritis occur with varying frequency. However, MVV and LVV can often involve the renal artery and its branches, causing a wide array of lesions that range from renal artery stenosis to intra-renal vasculitis causing renal ischaemia/infarction, microaneurysms and haemorrhage. This review focuses on renal involvement in MVV and LVV and underlines why renal abnormalities in these syndromes should not be overlooked.

Watts RA, Scott DG (1997) Classification and epidemiology of the vasculitides. Baillieres Clin Rheumatol 11(2):191–217CrossRefPubMed

Lightfoot RW Jr et al (1990) The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 33(8):1088–1093CrossRefPubMed

Jennette JC et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37(2):187–192CrossRefPubMed

Jennette JC et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11CrossRefPubMed

Palmisano A et al (2015) Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? Rheumatology (Oxford) 54(11):2004–2009CrossRef

Gonzalez-Gay MA et al (2005) Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 84(5):269–276CrossRef

Hutchinson J (1890) Diseases of the arteries. On a peculiar form of thrombotic arteries of the aged which is sometimes productive of gangrene. Arch Surg 1:323–329

Salvarani C, Cantini F, Hunder GG (2008) Polymyalgia rheumatica and giant-cell arteritis. Lancet 372(9634):234–245CrossRefPubMed

Hunder GG et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128CrossRefPubMed

10.

Carmona FD et al (2015) A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet 96(4):565–580CrossRefPubMedPubMedCentral

11.

Hailwood SJ et al (1999) Granulomatous vasculitis: an unusual renal vasculitis. Nephrol Dial Transplant 14(4):952–953CrossRefPubMed

12.

Scarpioni R et al (2003) Isolated renal giant cell arteritis, not so rare a cause of renal failure? Am J Kidney Dis 41(3):720CrossRefPubMed

13.

Truong L et al (1985) Temporal arteritis and renal disease. Case report and review of the literature. Am J Med 78(1):171–175CrossRefPubMed

14.

Moraga S et al (2001) Giant cell arteritis and renal amyloidosis: report of a case. Clin Nephrol 56(5):402–406PubMed

15.

Lie JT (1995) Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 24(6):422–431CrossRefPubMed

16.

Pipitone N, Versari A, Salvarani C (2008) Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. Rheumatology (Oxford) 47(4):403–408CrossRef

17.

Matteson EL et al (2016) Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. Rheum Dis Clin North Am 42(1):75–90CrossRefPubMed

18.

Tann OR, Tulloh RM, Hamilton MC (2008) Takayasu’s disease: a review. Cardiol Young 18(3):250–259CrossRefPubMed

19.

Arend WP et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33(8):1129–1134CrossRefPubMed

20.

Vanoli M et al (2005) Takayasu’s arteritis: a study of 104 Italian patients. Arthritis Rheum 53(1):100–107CrossRefPubMed

21.

Lagneau P, Michel JB (1985) Renovascular hypertension and Takayasu’s disease. J Urol 134(5):876–879PubMed

22.

Lai KN, Chan KW, Ho CP (1986) Glomerulonephritis associated with Takayasu’s arteritis: report of three cases and review of literature. Am J Kidney Dis 7(3):197–204CrossRefPubMed

23.

de Pablo P et al (2007) Kidney involvement in Takayasu arteritis. Clin Exp Rheumatol 25(1 Suppl 44):S10–S14PubMed

24.

Sharma BK, Jain S, Radotra BD (1998) An autopsy study of Takayasu arteritis in India. Int J Cardiol 66(Suppl 1):S85–S90 (discussion S91) CrossRefPubMed

25.

Boubaker K et al (2014) Renal injury in Takayasu’s arteritis. Nephrol Ther 10(6):451–456CrossRefPubMed

26.

Palmisano A, Vaglio A (2009) Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res Clin Rheumatol 23(3):339–353CrossRefPubMed

27.

Parums DV (1990) The spectrum of chronic periaortitis. Histopathology 16(5):423–431CrossRefPubMed

28.

van Bommel EF et al (2009) Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine (Baltimore) 88(4):193–201CrossRef

29.

Vaglio A et al (2007) Retroperitoneal fibrosis: evolving concepts. Rheum Dis Clin North Am 33(4):803–817 (vi–vii) CrossRefPubMed

30.

Martorana D et al (2006) Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. Arthritis Rheum 55(1):126–130CrossRefPubMed

31.

Boiardi L et al (2011) CC chemokine receptor 5 polymorphism in chronic periaortitis. Rheumatology (Oxford) 50(6):1025–1032CrossRef

32.

Goldoni M et al (2014) Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis: a case-control study. Ann Intern Med 161(3):181–188CrossRefPubMed

33.

Pelkmans LG et al (2012) Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant 27(7):2819–2825CrossRefPubMed

34.

Yamamoto M et al (2012) Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol 22(3):419–425CrossRefPubMed

35.

Brandt AS et al (2011) Associated findings and complications of retroperitoneal fibrosis in 204 patients: results of a urological registry. J Urol 185(2):526–531CrossRefPubMed

36.

Kermani TA et al (2011) Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc 86(4):297–303CrossRefPubMedPubMedCentral

37.

Vaglio A et al (2011) Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 378(9788):338–346CrossRefPubMed

38.

Vaglio A, Pipitone N, Salvarani C (2011) Chronic periaortitis: a large-vessel vasculitis? Curr Opin Rheumatol 23(1):1–6CrossRefPubMed

39.

Scheel PJ Jr, Feeley N (2009) Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore) 88(4):202–207CrossRef

40.

Palmisano A et al (2009) Peri-renal collateral circles. Urology 74(2):292–293CrossRefPubMed

41.

Sakata N et al (2008) IgG4-positive plasma cells in inflammatory abdominal aortic aneurysm: the possibility of an aortic manifestation of IgG4-related sclerosing disease. Am J Surg Pathol 32(4):553–559CrossRefPubMed

42.

Vaglio A et al (2002) ANCA-positive periaortic vasculitis: does it fall within the spectrum of vasculitis? J Intern Med 251(3):268–271CrossRefPubMed

43.

Khosroshahi A et al (2013) Rethinking Ormond’s disease: “idiopathic” retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore) 92(2):82–91CrossRef

44.

Corradi D et al (2007) Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int 72(6):742–753CrossRefPubMed

45.

Kottra JJ, Dunnick NR (1996) Retroperitoneal fibrosis. Radiol Clin North Am 34(6):1259–1275PubMed

46.

Salvarani C et al (2005) Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum 53(2):298–303CrossRefPubMed

47.

Kardar AH et al (2002) Steroid therapy for idiopathic retroperitoneal fibrosis: dose and duration. J Urol 168(2):550–555CrossRefPubMed

48.

Warnatz K et al (2005) Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature. Ann Rheum Dis 64(6):828–833CrossRefPubMedPubMedCentral

49.

Hernandez-Rodriguez J et al (2014) Diagnosis and classification of polyarteritis nodosa. J Autoimmun 48–49:84–89CrossRefPubMed

50.

Watts RA et al (2000) Epidemiology of systemic vasculitis: a 10-year study in the United Kingdom. Arthritis Rheum 43(2):414–419CrossRefPubMed

51.

Trepo C, Thivolet J (1970) Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 19(3):410–411CrossRefPubMed

52.

Guillevin L et al (2005) Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 84(5):313–322CrossRef

53.

Navon Elkan P et al (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370(10):921–931CrossRefPubMed

54.

Pagnoux C et al (2010) Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 62(2):616–626CrossRefPubMed

55.

el-Reshaid K et al (1997) The spectrum of renal disease associated with microscopic polyangiitis and classic polyarteritis nodosa in Kuwait. Nephrol Dial Transplant 12(9):1874–1882CrossRefPubMed

56.

Cohen RD, Conn DL, Ilstrup DM (1980) Clinical features, prognosis, and response to treatment in polyarteritis. Mayo Clin Proc 55(3):146–155PubMed

57.

Gorriz JL et al (1997) Renal-limited polyarteritis nodosa presenting with loin pain and haematuria. Nephrol Dial Transplant 12(12):2737–2739CrossRefPubMed

58.

Kaur JS, Goldberg JP, Schrier RW (1982) Acute renal failure following arteriography in a patient with polyarteritis nodosa. JAMA 247(6):833–834CrossRefPubMed

59.

Wang AY et al (1996) Acute renal failure induced by angiotensin converting enzyme inhibitor in a patient with polyarteritis nodosa. Ren Fail 18(2):293–298CrossRefPubMed

60.

Ladefoged J et al (1969) Acute anuria due to polyarteritis nodosa. Am J Med 46(5):827–831CrossRefPubMed

61.

Schlesinger M et al (1989) Perirenal and renal subcapsular haematoma as presenting symptoms of polyarteritis nodosa. Postgrad Med J 65(767):681–683CrossRefPubMedPubMedCentral

62.

Peterson C Jr et al (1970) Polyarteritis nodosa with bilateral renal artery aneurysms and perirenal haematomas: angiographic and nephrotomographic features. Br J Radiol 43(505):62–66CrossRefPubMed

63.

Romijn JA et al (1989) Bilateral kidney rupture with severe retroperitoneal bleeding in polyarteritis nodosa. Neth J Med 35(5–6):260–266PubMed

64.

Hekali PE et al (1984) Bilateral renal artery dissections: unusual complication of polyarteritis nodosa. Eur J Radiol 4(1):6–8PubMed

65.

Glanz I, Grunebaum M (1976) Ureteral changes in polyarteritis nodosa as seen during excretory urography. J Urol 116(6):731–733PubMed

66.

Travers RL et al (1979) Polyarteritis nodosa: a clinical and angiographic analysis of 17 cases. Semin Arthritis Rheum 8(3):184–199CrossRefPubMed

67.

Schmidt WA (2004) Use of imaging studies in the diagnosis of vasculitis. Curr Rheumatol Rep 6(3):203–211CrossRefPubMed

68.

Guillevin L et al (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90(1):19–27CrossRef

69.

Ribi C et al (2010) Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients. Arthritis Rheum 62(4):1186–1197CrossRefPubMed

70.

Guillevin L et al (2003) Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 49(1):93–100CrossRefPubMed

Title: Kidney involvement in medium- and large-vessel vasculitis
Authors: Federica Maritati
Francesco Iannuzzella
Maria P. Pavia
Sonia Pasquali
Augusto Vaglio
Publication date: 01-08-2016
Publisher: Springer International Publishing
Published in: Journal of Nephrology / Issue 4/2016
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-016-0303-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Kidney involvement in medium- and large-vessel vasculitis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease

Up-to date of glomerular disease

Lessons from genetics: is it time to revise the therapeutic approach to children with steroid-resistant nephrotic syndrome?

Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms

IgM nephropathy: is it closer to minimal change disease or to focal segmental glomerulosclerosis?

IgG4-related nephropathy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page